GlassScriptPhysician profile
Christopher L Thompson
NPI 1740321447
$2,222.51
in general payments reported to CMS, 2019-2025
24 companies · $139 in 2025
The $139 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $40.58 · 2021: $224 · 2022: $895 · 2023: $679 · 2024: $244 · 2025: $139.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $625 · Long Term Medical Supply Or Device Loan: $283 · Education: $155.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $624.51 |
| Long Term Medical Supply Or Device Loan | $282.73 |
| Education | $154.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $982.64 | 2021-2025 | |
| Pfizer INC. | $261.36 | 2022-2023 | |
| E.R. Squibb & Sons, L.L.C. | $132.45 | 2021-2024 | Opdivo |
| Astrazeneca Pharmaceuticals LP | $115.12 | 2019-2025 | Imfinzi |
| Epizyme, INC. | $100.24 | 2021 | |
| Genentech USA, INC. | $60.74 | 2019-2022 | |
| G1 Therapeutics, INC. | $58.72 | 2022-2023 | Cosela |
| Incyte Corporation | $52.64 | 2022-2024 | Jakafi, Pemazyre, Monjuvi |
| Merck Sharp & Dohme LLC | $51.37 | 2022-2023 | Lynparza, Keytruda |
| Abbvie INC. | $48.87 | 2023-2024 | Venclexta |
| Ipsen Biopharmaceuticals, INC | $48.69 | 2024 | Tazverik, Onivyde |
| Astellas Pharma US INC | $41.16 | 2021-2024 | Padcev |
| Recordati_rare_diseases_inc. | $31.69 | 2024 | Sylvant |
| Seagen INC. | $29.96 | 2021-2022 | |
| Genzyme Corporation | $28.98 | 2023 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $28.27 | 2021-2022 | |
| Sumitomo Pharma America, INC. | $24.36 | 2023 | Orgovyx |
| Rigel Pharmaceuticals, INC. | $21.28 | 2019-2023 | Rezlidhia, Tavalisse |
| Celgene Corporation | $21.23 | 2022 | |
| Myovant Sciences INC. | $21.06 | 2021 | |
| Emd Serono, INC. | $18.15 | 2023 | Tepmetko |
| Daiichi Sankyo INC. | $16.36 | 2022 | |
| Acrotech Biopharma INC. | $13.93 | 2022 | |
| Taiho Oncology, INC. | $13.24 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christopher Thompson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.